Top

Published in:

Open Access 01-12-2019 | Ovarian Cancer | Research

Postoperative recurrence of epithelial ovarian cancer patients and chemoresistance related protein analyses

Authors: Zhengmao Zhang, Kaiyun Qin, Wenzhe Zhang, Botao Yang, Chen Zhao, Xiaojing Zhang, Fenghua Zhang, Lianmei Zhao, Baoen Shan

Published in: Journal of Ovarian Research | Issue 1/2019

Abstract

Objective

To identify the plasma protein biomarkers related to the chemoresistance of postoperative recurrence of epithelial ovarian cancers.

Methods

Forty plasma samples from patients in chemotherapy-sensitive and chemotherapy-resistant groups (20 for each group) were collected at Gynecology Department in the Fourth Hospital of Hebei Medical University from September 2013 to September 2014. The differentially expressed proteins between two groups were screened with two-dimensional gel electrophoresis (2-DE) and further analyzed by matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF–MS).

Results

Thirty-four differentially expressed spots were identified between the two groups. Compared with the chemo-sensitive group, 21 protein spots were up-regulated and 13 were down-regulated in the chemoresistant group, in which 14 differentially expressed proteins were identified by the Mass spectrometry and Mascot search. Among the 14 proteins, complement C4-A, IgJ chain, clusterin, α-1-antitrypsin and carbonic anhydrase 1 were up-regulated, and transthyretin, haptoglobin, β-2-glycoprotein, Ig γ-2 chain C region, Ig γ-1 chain C region, complement factor I light chain, Igκ chain C region, complement C3 and apolipoprotein E were down-regulated in the chemoresistant group when compared with the chemosensitive group.

Conclusion

The up-regulated proteins including transthyretin, apolipoprotein E and haptoglobin proteins and the down-regulated proteins such as clusterin, carbonic anhydrase 1, alpha-1-antitrypsin were differentially expressed in the plasma between the chemo-sensitive group and the chemoresistant group, which may be potential biomarkers for predicting the chemotresistance of epithelial ovarian cancer patients.

Sood AK, Buller RE. Drug resistance in ovarian cancer: from the laboratory to the clinic. Obstet Gynecol. 1998;92(2):312–9.PubMed

Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007;14(5):195–208.CrossRef

Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and bowel project protocol B-27. J Clin Oncol. 2006;24(13):2019–27. https://doi.org/10.1200/JCO.2005.04.1665.CrossRefPubMed

Broxterman HJ, Gotink KJ, Verheul HM. Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat. 2009;12(4–5):114–26. https://doi.org/10.1016/j.drup.2009.07.001.CrossRefPubMed

Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics. 2005;5(17):4589–96. https://doi.org/10.1002/pmic.200500093.CrossRefPubMed

Sensibar JA, Sutkowski DM, Raffo A, Buttyan R, Griswold MD, Sylvester SR, et al. Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res. 1995;55(11):2431–7.PubMed

Jenne DE, Tschopp J. Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid. Proc Natl Acad Sci U S A. 1989;86(18):7123–7.CrossRef

Davidson B, Trope CG. Ovarian cancer: diagnostic, biological and prognostic aspects. Women's health. 2014;10(5):519–33. https://doi.org/10.2217/whe.14.37.CrossRefPubMed

Refai E, Dekki N, Yang SN, Imreh G, Cabrera O, Yu L, et al. Transthyretin constitutes a functional component in pancreatic beta-cell stimulus-secretion coupling. Proc Natl Acad Sci U S A. 2005;102(47):17020–5. https://doi.org/10.1073/pnas.0503219102.CrossRefPubMedPubMedCentral

10.

Su Y, Jono H, Misumi Y, Senokuchi T, Guo J, Ueda M, et al. Novel function of transthyretin in pancreatic alpha cells. FEBS Lett. 2012;586(23):4215–22. https://doi.org/10.1016/j.febslet.2012.10.025.CrossRefPubMed

11.

Huang H, Li Y, Liu J, Zheng M, Feng Y, Hu K, et al. Screening and identification of biomarkers in ascites related to intrinsic chemoresistance of serous epithelial ovarian cancers. PLoS One. 2012;7(12):e51256. https://doi.org/10.1371/journal.pone.0051256.CrossRefPubMedPubMedCentral

12.

Fritz IB, Burdzy K, Setchell B, Blaschuk O. Ram rete testis fluid contains a protein (clusterin) which influences cell-cell interactions in vitro. Biol Reprod. 1983;28(5):1173–88.CrossRef

13.

Sylvester SR, Morales C, Oko R, Griswold MD. Localization of sulfated glycoprotein-2 (clusterin) on spermatozoa and in the reproductive tract of the male rat. Biol Reprod. 1991;45(1):195–207.CrossRef

14.

Jenne DE, Lowin B, Peitsch MC, Bottcher A, Schmitz G, Tschopp J. Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. J Biol Chem. 1991;266(17):11030–6.PubMed

15.

Wei L, Xue T, Wang J, Chen B, Lei Y, Huang Y, et al. Roles of clusterin in progression, chemoresistance and metastasis of human ovarian cancer. Int J Cancer. 2009;125(4):791–806. https://doi.org/10.1002/ijc.24316.CrossRefPubMed

16.

Xie D, Sham JS, Zeng WF, Che LH, Zhang M, Wu HX, et al. Oncogenic role of clusterin overexpression in multistage colorectal tumorigenesis and progression. World J Gastroenterol. 2005;11(21):3285–9.CrossRef

17.

Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W, et al. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ. 2006;13(1):12–9. https://doi.org/10.1038/sj.cdd.4401779.CrossRefPubMed

18.

Cheng ZZ, Corey MJ, Parepalo M, Majno S, Hellwage J, Zipfel PF, et al. Complement factor H as a marker for detection of bladder cancer. Clin Chem. 2005;51(5):856–63. https://doi.org/10.1373/clinchem.2004.042192.CrossRefPubMed

19.

Li J, Orlandi R, White CN, Rosenzweig J, Zhao J, Seregni E, et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem. 2005;51(12):2229–35. https://doi.org/10.1373/clinchem.2005.052878.CrossRefPubMed

20.

He P, He HZ, Dai J, Wang Y, Sheng QH, Zhou LP, et al. The human plasma proteome: analysis of Chinese serum using shotgun strategy. Proteomics. 2005;5(13):3442–53. https://doi.org/10.1002/pmic.200401301.CrossRefPubMed

21.

Zane HD. Immunology [M]Philadelphia:WB Saunders Co. 2001:129–135.

22.

Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360–5. https://doi.org/10.1073/pnas.0611533104.CrossRefPubMedPubMedCentral

23.

Zeimet AG, Reimer D, Wolf D, Fiegl H, Concin N, Wiedemair A, et al. Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer. Int J Cancer. 2009;124(10):2353–60. https://doi.org/10.1002/ijc.24214.CrossRefPubMed

24.

Zhang Z, Huang J, Zhang C, Yang H, Qiu H, Li J, et al. Infiltration of dendritic cells and T lymphocytes predicts favorable outcome in epithelial ovarian cancer. Cancer Gene Ther. 2015;22(4):198–206. https://doi.org/10.1038/cgt.2015.7.CrossRefPubMed

Title: Postoperative recurrence of epithelial ovarian cancer patients and chemoresistance related protein analyses
Authors: Zhengmao Zhang
Kaiyun Qin
Wenzhe Zhang
Botao Yang
Chen Zhao
Xiaojing Zhang
Fenghua Zhang
Lianmei Zhao
Baoen Shan
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Ovarian Cancer
Ovarian Cancer
Cytostatic Therapy
Published in: Journal of Ovarian Research / Issue 1/2019
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/s13048-019-0499-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Postoperative recurrence of epithelial ovarian cancer patients and chemoresistance related protein analyses

Abstract

Objective

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

CYPA promotes the progression and metastasis of serous ovarian cancer (SOC) in vitro and in vivo

Risk factors for postoperative recurrence of ovarian endometriosis: long-term follow-up of 358 women

miR-552 promotes ovarian cancer progression by regulating PTEN pathway

Comparison and analysis of the clinicopathological features of SCEO and ECOM

Quercetin: a natural compound for ovarian cancer treatment

Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis